However, in transplant-age patients with the CALR mutation, symptoms response was significantly lower (52.5% versus 69.3% in JAK2-mutated patients, p = 0.01) and overall anemia rate was higher (55.4% versus 42.9%, p = 0.05). Here, JAK2 is linked to anemia.